Merlin Sardis
Research Subjects
Merlin Sardis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Andra Noormägi
Department of Chemistry and Biotechnology
1 shared publication- Astrid Gräslund
Department of Biochemistry and Biophysics
1 shared publication - Jüri Jarvet
Department of Biochemistry and Biophysics, Stockholm University, 106 91 Stockholm, Sweden
1 shared publication - Peep Palumaa
Department of Chemistry and Biotechnology, Tallinn University of Technology, Akadeemia tee 15, 12618 Tallinn, Estonia
1 shared publication - Sebastian K. T. S. Wärmländer
Chemistry Section, Arrhenius Laboratories, Stockholm University, 106 91 Stockholm, Sweden
1 shared publication Vello Tõugu
Department of Chemistry and Biotechnology
1 shared publication
Latest Publications
- Open Access
- 3 February 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (6) , 10626-10631
Binding of ApoE Isoforms to Aβ Peptides and Effects on Their Fibrillization
Alzheimer’s disease (AD) is the most widespread neurodegenerative disease, strongly linked to amyloid depositions in the brain consisting of amyloid β (Aβ) peptides. The likelihood of developing late-onset Alzheimer’s disease (LOAD) is influenced by the specific isoforms of apolipoprotein E (ApoE), with ApoE4 being the strongest known genetic risk factor for LOAD. Strong evidence suggests that ApoE impacts AD by modulating Aβ aggregation and clearance, although the precise molecular mechanisms remain incompletely understood. Microscale thermophoresis (MST) is a powerful technique for characterizing molecular interactions in solution, which has been used to determine various binding constants, although not the binding of ApoE to Aβ peptides. MST results show that ApoE isoforms bind Aβ1–40 and Aβ1–42 with low micromolar affinity. For Aβ1–42, ApoE3 shows the strongest binding (K d = 0.72 μM) and ApoE4 shows the weakest binding (K d = 2.80 μM). For Aβ1–40, ApoE4 shows the strongest binding (K d = 1.59 μM) and ApoE2 shows the weakest binding (K d = 5.29 μM). The MST results show that ApoE interacts with Aβ peptides at supraphysiological peptide concentrations. However, ApoE inhibited the fibrillization of Aβ1–42 peptide at substoichiometric concentrations, which might be related to blocking Aβ fibril elongation in vivo. The estimated IC50 values indicate that ApoE4 has a slightly stronger, and ApoE2 a slightly weaker, inhibitory effect on Aβ1–42 fibrillization.
- 3 February 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (6) , 10626-10631
Open AccessBinding of ApoE Isoforms to Aβ Peptides and Effects on Their Fibrillization
Alzheimer’s disease (AD) is the most widespread neurodegenerative disease, strongly linked to amyloid depositions in the brain consisting of amyloid β (Aβ) peptides. The likelihood of developing late-onset Alzheimer’s disease (LOAD) is influenced by the specific isoforms of apolipoprotein E (ApoE), with ApoE4 being the strongest known genetic risk factor for LOAD. Strong evidence suggests that ApoE impacts AD by modulating Aβ aggregation and clearance, although the precise molecular mechanisms remain incompletely understood. Microscale thermophoresis (MST) is a powerful technique for characterizing molecular interactions in solution, which has been used to determine various binding constants, although not the binding of ApoE to Aβ peptides. MST results show that ApoE isoforms bind Aβ1–40 and Aβ1–42 with low micromolar affinity. For Aβ1–42, ApoE3 shows the strongest binding (K d = 0.72 μM) and ApoE4 shows the weakest binding (K d = 2.80 μM). For Aβ1–40, ApoE4 shows the strongest binding (K d = 1.59 μM) and ApoE2 shows the weakest binding (K d = 5.29 μM). The MST results show that ApoE interacts with Aβ peptides at supraphysiological peptide concentrations. However, ApoE inhibited the fibrillization of Aβ1–42 peptide at substoichiometric concentrations, which might be related to blocking Aβ fibril elongation in vivo. The estimated IC50 values indicate that ApoE4 has a slightly stronger, and ApoE2 a slightly weaker, inhibitory effect on Aβ1–42 fibrillization.